At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,621 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
HUMIRA® 40 mg Syringe 0.8 mL for Subcutaneous Injection Protocol for Special Investigation on Long-Term Administration Ulcerative Colitis
In Brief
An observational study for Ulcerative Colitis. Completed, enrolled 1,621 participants.
Detailed Summary
This investigation will be conducted to obtain the following information regarding the use of Humira 40 mg Syringe 0.8 mL for Subcutaneous Injection in patients with Ulcerative Colitis. 1. Unknown adverse reactions (in particular, clinically significant) 2. Incidence and conditions of occurrence of adverse reactions in clinical practice 3. Factors likely to affect the safety and effectiveness
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis
Countries--
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartAug 2013
First PostedSep 2013
Primary CompletionFeb 2018
TodayJul 2026
First PostedSep 23, 2013
Enrollment StartAug 9, 2013
Primary CompletionFeb 15, 2018
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 12.8 years ago